[go: up one dir, main page]

MX2008011127A - INHIBIDOR DE 17ß HSD TIPO 5. - Google Patents

INHIBIDOR DE 17ß HSD TIPO 5.

Info

Publication number
MX2008011127A
MX2008011127A MX2008011127A MX2008011127A MX2008011127A MX 2008011127 A MX2008011127 A MX 2008011127A MX 2008011127 A MX2008011127 A MX 2008011127A MX 2008011127 A MX2008011127 A MX 2008011127A MX 2008011127 A MX2008011127 A MX 2008011127A
Authority
MX
Mexico
Prior art keywords
hsd type
carboxy
group
prostate
cancer
Prior art date
Application number
MX2008011127A
Other languages
English (en)
Inventor
Akio Kakefuda
Akio Kamikawa
Masaaki Hirano
Yasushi Amano
Tomohiko Yamaguchi
Kenichi Suzumura
Kentaro Enjo
Takashi Furutani
Yutaka Kondoh
Tatsuya Niimi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2008011127A publication Critical patent/MX2008011127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se desea proporcionar un nuevo y excelente método para tratar y/o prevenir el cáncer de próstata, ampliación de próstata, acné, seborrea, hipertricosis, calvicie, alopecia, precocidad sexual, hipertrofia suprarrenal, síndrome del ovario multilocular, cáncer de mama, cáncer de pulmón, endometriosis, leiomioma y así basado en un efecto selectivamente para inhibir 17ß HSD tipo 5. Se ha encontrado que un derivado de N-sulfonilindol, en el cual un átomo de carbono en el grupo indol es sustituido por un grupo carboxi, un grupo alquilo inferior sustituido por carboxi o un grupo alquenilo inferior sustituido por carboxi, tiene una actividad potente para selectivamente inhibir 17ß HSD tipo 5 y usable como un remedio y/o preservativo para enfermedades, en donde 17ß HSD tipo 5 participa, tal como aplicación de próstata y cáncer de próstata sin mostrar ningún efecto secundario causado por una disminución en la testosterona.
MX2008011127A 2006-03-02 2007-03-01 INHIBIDOR DE 17ß HSD TIPO 5. MX2008011127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006056827 2006-03-02
PCT/JP2007/053976 WO2007100066A1 (ja) 2006-03-02 2007-03-01 １７βＨＳＤｔｙｐｅ５阻害剤

Publications (1)

Publication Number Publication Date
MX2008011127A true MX2008011127A (es) 2008-10-31

Family

ID=38459165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011127A MX2008011127A (es) 2006-03-02 2007-03-01 INHIBIDOR DE 17ß HSD TIPO 5.

Country Status (8)

Country Link
US (2) US7855225B2 (es)
EP (1) EP1990335A4 (es)
JP (1) JP5093096B2 (es)
KR (1) KR20080114711A (es)
CN (1) CN101395134B (es)
CA (1) CA2644809A1 (es)
MX (1) MX2008011127A (es)
WO (1) WO2007100066A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
BRPI0806371A2 (pt) * 2007-01-22 2011-09-13 Gtx Inc agentes ligação de receptor nuclear
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
MX2010000918A (es) * 2007-07-24 2010-03-15 Astellas Pharma Inc Derivado de bencimidazol.
WO2009028618A1 (ja) * 2007-08-31 2009-03-05 Astellas Pharma Inc. ピペリジン誘導体
JPWO2010087319A1 (ja) * 2009-01-27 2012-08-02 アステラス製薬株式会社 前立腺癌治療剤として有効な物質のスクリーニング方法
JP5609150B2 (ja) * 2009-02-27 2014-10-22 アステラス製薬株式会社 ピペリジン誘導体
EP2488524B1 (en) * 2009-10-15 2013-07-03 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
WO2012025638A1 (en) * 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
EP2669270B1 (en) 2011-01-28 2018-01-03 Sato Pharmaceutical Co., Ltd. Indole-related compounds as urat1 inhibitors
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
BR112015000443A2 (pt) 2012-07-10 2017-06-27 Bayer Pharma AG derivados de estra-1,3,5(10),16-tetraeno 3-substituídos, processo para a sua produção, preparações farmacêuticas que contêm os mesmos, bem como seu uso para a produção de medicamentos
DK2878594T3 (en) 2012-07-27 2019-02-04 Sato Pharma DIFLUOROMETHYLENE COMPOUND
PE20151754A1 (es) 2013-02-21 2015-12-20 Bayer Pharma AG Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017163263A1 (en) 2016-03-22 2017-09-28 Council Of Scientific & Industrial Research Indole derivatives, preparation and use thereof
US10167293B2 (en) * 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
EP3351544A1 (en) * 2017-01-12 2018-07-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzene disulfonamide for the treatment of cancer
EP3421483A1 (en) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Novel steroidal 17-beta heteroaryl compounds as inhibitors of akr1c3
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
EP4051283A4 (en) * 2019-11-01 2024-03-27 The Regents of the University of California P53 MODULATORS AND USES THEREOF
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004301D0 (en) * 1990-02-26 1990-04-18 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5283251A (en) 1990-02-26 1994-02-01 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
GB9116732D0 (en) 1991-08-02 1991-09-18 Fujisawa Pharmaceutical Co Indole derivatives
NZ250916A (en) * 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
JPH09104675A (ja) 1995-10-06 1997-04-22 Soyaku Gijutsu Kenkyusho:Kk 新規なピリドン誘導体
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
JP3783810B2 (ja) * 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
WO1998050356A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
RU2000125533A (ru) * 1998-03-11 2002-10-20 Эндорешерш, Инк. (Ca) Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения
IL137974A0 (en) 1998-03-26 2001-10-31 Shionogi & Co Indole derivatives having antiviral activity
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
CO5180605A1 (es) 1999-06-23 2002-07-30 Smithkline Beecham Corp Compuestos de indol
US6249159B1 (en) * 1999-12-30 2001-06-19 Intel Corporation Frequency control circuit having increased control bandwidth at lower device operating speed
AU2002211901A1 (en) 2000-10-10 2002-04-22 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as PPAR-gamma binding agents
CA2432114A1 (en) * 2000-12-20 2002-07-18 Sugen, Inc. 4-(hetero)aryl substituted indolinones
AU2002258550B2 (en) 2001-03-14 2006-04-27 Eli Lilly And Company Retinoid X receptor modulators
WO2003068220A1 (en) 2002-02-12 2003-08-21 Akzo Nobel N.V. 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders
KR20050098250A (ko) 2003-01-17 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 에너골리틱제를 사용한 양성 전립선 비대증의 치료 방법
US7754709B2 (en) 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
AU2004259738B2 (en) 2003-07-17 2011-11-17 Plexxikon, Inc. PPAR active compounds
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
EP1758884A2 (en) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006010008A1 (en) 2004-06-22 2006-01-26 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
SG165362A1 (en) 2005-09-07 2010-10-28 Plexxikon Inc Ppar active compounds
JP2009509932A (ja) 2005-09-07 2009-03-12 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物

Also Published As

Publication number Publication date
CN101395134B (zh) 2011-08-31
EP1990335A1 (en) 2008-11-12
JP5093096B2 (ja) 2012-12-05
EP1990335A4 (en) 2009-11-11
US7855225B2 (en) 2010-12-21
US20090181960A1 (en) 2009-07-16
JPWO2007100066A1 (ja) 2009-07-30
CA2644809A1 (en) 2007-09-07
US20110071146A1 (en) 2011-03-24
KR20080114711A (ko) 2008-12-31
CN101395134A (zh) 2009-03-25
WO2007100066A1 (ja) 2007-09-07

Similar Documents

Publication Publication Date Title
MX2008011127A (es) INHIBIDOR DE 17ß HSD TIPO 5.
ATE438402T1 (de) 4-anilino-chinazolin-derivate als proliferationshemmende mittel
IL187586A0 (en) Method for producing dihydroquinazolines
ATE533485T1 (de) Cetp-inhibitoren
TNSN07325A1 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
MX2010001340A (es) Combianacion de agente antimitotico e inhibidor de aurora quinasa como tratamiento anticancerigeno.
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MX2010002692A (es) Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.
MX2008009564A (es) Sistema de energia mareomotriz.
TW200628158A (en) Promoting neochondrogenesis using kinase inhibitors
MX2010007391A (es) Antagonistas de trpa1.
NZ603343A (en) Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
MX2010007392A (es) Antagonistas de trpa1.
UA97872C2 (ru) Производные индолинона и способы их получения
NZ592640A (en) Improved dc bus regulator
MY193210A (en) Process for producing diazabicyclooctane derivative
ATE522672T1 (de) Vorrichtung zum befestigen eines wandhängenden objektes
GB0510584D0 (en) Organic compounds
MX2010005395A (es) Metodo para tratar artritis.
MX2007014172A (es) Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
MX2009004314A (es) Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
ATE511554T1 (de) Verfahren und system zum galvanisieren durch plasmaverdampfung
DE602006008291D1 (de) Chinazolinderivate als inhibitoren von egf und/oder erbb2-rezeptortyrosinkinase
WO2009014150A1 (ja) ベンズイミダゾール誘導体

Legal Events

Date Code Title Description
FA Abandonment or withdrawal